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Background: While eradicating racial disparities in cardiovascular care is a national priority, little is known about racial differences in rates of 
compliance to outpatient cardiovascular performance measures (PMs).
Methods: We evaluated whether black patients were as likely as white patients to receive established ACC/AHA PMs among patients enrolled into 
the ACC’s IC3 (Improving Continuous Cardiac Care) Program; the first prospective, office-based, cardiac quality improvement program in the U.S. 
Using modified Poisson regression models adjusted for site, physician, age, and sex, we compared compliance rates between blacks and whites for 7 
select coronary artery disease (CAD), heart failure (HF) and atrial fibrillation PMs during their initial enrolment visit into IC3.
Results: There were a total of 12,261 patients enrolled from 20 practices during 7/08 to 6/09, of which 2234 (18.2%) were of black race. For 
CAD, rates of PM compliance were similar between black and white patients for use of beta-blockers after myocardial infarction (86.0% for whites, 
89.5% for blacks; adjusted Rate Ratio [aRR], 1.03 [95% CI: 0.96-1.10]; p=0.42), antiplatelet therapy (84.5% vs. 89.1%; aRR, 1.01 [0.98-1.04]; 
p=0.73), lipid lowering therapy (84.8% vs. 84.0%; aRR, 0.98 [0.92-1.05]; p=0.60), and ACE inhibitor or ARB therapy for left ventricular systolic 
dysfunction (LVEF <40%) (72.5% vs. 79.3%; aRR, 1.01 [0.96-1.07]; p=0.64). For HF with left ventricular dysfunction, βετα-blocker use was similar 
for black and white patients (92.5% vs. 92.6%; aRR, 0.98 [0.93-1.02]; p=0.34), but blacks were less likely to receive ACE inhibitor or ARB therapy 
(84.8% vs. 85.3%; aRR, 0.93 [0.86-1.00]; p=0.05). The use of warfarin was similar in eligible patients with atrial fibrillation (79.3% vs. 79.2%; aRR, 
1.01 [0.91-1.12]; p=0.90).
Conclusions: Initial insights into the quality of outpatient care suggest comparable compliance rates for blacks and whites in key PMs among 
the early participants in the IC3 Program, although small differences were observed for ACEI/ARB use in eligible HF patients. Importantly, adherence 
rates among ideal patients ranged from 72%-93% suggesting an opportunity to improve care for all patients.
